Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAG1 | P54619 | 13/20 | 0.76 |
| ▸ | PRKAB1 | Q9Y478 | 13/20 | 0.76 |
| ▸ | PRKAA2 | P54646 | 10/20 | 0.76 |
| ▸ | PRKAA1 | Q13131 | 7/20 | 0.76 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.76 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.76 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.76 |
| ▸ | TFDP2 | Q14188 | 1/20 | 0.76 |
| ▸ | DHODH | Q02127 | 5/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3481141 | 0.94 | PRKAG1 (0.84) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437421 | 0.91 | PRKAG1 (0.80) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437359 | 0.91 | PRKAG1 (0.80) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437535 | 0.91 | PRKAG1 (0.63) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437480 | 0.90 | PRKAG1 (0.69) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL3163783 | 0.89 | PRKAG1 (0.68) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437301 | 0.88 | PRKAG1 (0.96) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| Ammonia Solution, Strong SCHEMBL3481233 | 0.88 | PRKAG1 (0.67) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| Ammonia Solution, Strong SCHEMBL3481236 | 0.88 | PRKAG1 (0.67) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 | |
| SCHEMBL13437443 | 0.88 | PRKAG1 (0.75) | PRKAG1PRKAB1PRKAA2PRKAA1PRKAB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394969-B2 | Cyclic benzimidazole derivatives useful as anti-diabetic agents | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| WO-2013006526-A2 | TRICYCLIC HETEROCYCLES USEFUL AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012096813-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012064569-A1 | IMIDAZOLE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012024179-A1 | SUBSTITUTED AMIDE DERIVATIVES AS DGAT-1 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011127643-A1 | PYRIDONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011037771-A1 | DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM | MERCK SHARP & DOHME CORP. (US) | 2011-03-31 | — | — | WO | disclosed |
| WO-2010108268-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010094126-A1 | HETEROCYCLIC DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010043052-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-04-22 | — | — | WO | disclosed |
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | MERCK SHARP & DOHME LLC | 2010-04-01 | — | — | US | disclosed |
| WO-2010025553-A1 | HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081643-A1 | NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS | PRKAG2, PRKAG1, PRKAB2 | PRKAG1 2/4885PRKAB1 5/4885PRKAA2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.